Langerinⁿᵉᵍ conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 110; no. 26; pp. 10723 - 10728
• Main Authors: Wohn, Christian, Ober-Blöbaum, Julia L., Haak, Stefan, Pantelyushin, Stanislav, Cheong, Cheolho, Zahner, Sonja P., Onderwater, Sabina, Kant, Marius, Weighardt, Heike, Holzmann, Bernhard, Reizis, Boris, Becher, Burkhard, Prens, Errol P., Clausen, Björn E.
• Format: Journal Article
• Language: English
• Published: National Academy of Sciences 25.06.2013; National Acad Sciences
• Subjects: Biological Sciences
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.1307569110

Psoriasis is an autoinflammatory skin disease of unknown etiology. Topical application of Aldara cream containing the Toll-like receptor (TLR)7 agonist Imiquimod (IMQ) onto patients induces flares of psoriasis. Likewise, in mice IMQ triggers pathological changes closely resembling psoriatic plaque formation. Key cytokines like IL-23 and type-I IFN (IFN-I), both being produced mainly by dendritic cells (DCs), have been implicated in psoriasis. Although plasmacytoid DCs (pDCs) are the main source of IFNα and thought to initiate disease, conventional DCs (cDCs) appear to maintain the psoriatic lesions. Any role of cDCs during lesion formation remains elusive. Here, we report that selective activation of TLR7 signaling specifically in CD11c ⁺ DCs was sufficient to induce psoriasiform skin disease in mice. Intriguingly, both pDCs and the IFN-I pathway were dispensable for the development of local skin inflammation. Selective TLR7 triggering of Langerin ⁺ DCs resulted in attenuated disease, whereas their depletion did not alter the severity of skin lesions. Moreover, after IMQ-painting, IL-23 was exclusively produced by Langerin ⁿᵉᵍ DCs in vivo. In conclusion, TLR7-activated Langerin ⁿᵉᵍ cDCs trigger psoriatic plaque formation via IL-23–mediated activation of innate IL-17/IL-22–producing lymphocytes, independently of pDCs or IFN-I. These results suggest therapeutic targeting of IL-23 production by cDCs to refine current treatment strategies for psoriasis.